Skip to main content

Advertisement

SpringerLink
Log in

Transsphenoidal surgery for microprolactinomas in women: results and prognosis

  • Clinical Article
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Background

Long-term dopamine agonist (DA) therapy is recommended as a first-line approach for the management of microprolactinomas. However, DA therapy may be poorly tolerated by some patients, and therefore some patients continue to prefer surgery over DA therapy.

Aim

The aim of our study was to evaluate factors associated with favorable outcomes after surgical treatment of microprolactinomas in women.

Methods

Thirty-two women (mean age 31.0 ± 8.2 years) with confirmed microprolactinomas who were operated using transsphenoidal approach were included to the study. Twenty-two (61 %) women had previous DA therapy and ten (39 %) women preferred surgery as a first treatment. Mean follow-up was 4.2 ± 2.7 years. Surgery was considered to be effective and remission achieved if serum prolactin was normal without DA therapy and there were no signs of tumor re-growth on neuroimaging.

Results

Nine (47.4 %) patients in whom remission was achieved did not receive preoperative DA therapy when compared to one (7.7 %) patient in whom remission was not achieved (p = 0.02). Remission after operation was achieved in nine out of ten (90 %) patients who did not receive DA therapy compared to ten out of 22 patients (45.5 %) who were treated with DAs (p = 0.01). The independent factor associated with good outcome following surgical treatment was no preoperative DA therapy (RR = 14.57 (1.43–148.1), p = 0.02). Surgical complications were permanent diabetes insipidus in two patients (6.3 %) and transient DI in five (15.6 %) patients.

Conclusions

The main factor associated with favorable microprolactinoma surgery outcome in women was the absence of preoperative DA therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Acharya V (2004) Review of pregnancy reports in patients on pergolide treatment. Eli Lilly, Co., Indianapolis

    Google Scholar 

  2. Amar AP, Couldwell WT, Chen JCT, Weiss MH (2002) Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 97:307–314

    Article  PubMed  CAS  Google Scholar 

  3. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273

    Article  Google Scholar 

  4. Couldwell WT, Rovit RL, Weiss MH (2003) Role of surgery in the treatment of microprolactinomas. Neurosurg Clin N Am 14:89–92

    Article  PubMed  Google Scholar 

  5. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocrinol Rev 27:485–534

    Article  CAS  Google Scholar 

  6. Guieu R, Dufour H, Grisoli F, Jaquet P, Guieu Y, Rosso JP, Munier M, Dicostanzo V, Brue T, Enjalbert A, Begoud D, Rochat H (1999) An ultrarapid prognostic index in microprolactinoma surgery. J Neurosurg 90:1037–1041

    Article  PubMed  CAS  Google Scholar 

  7. Hamilton DK, Vance ML, Boulos PT, Laws ER (2005) Surgical outcoms in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8(1):53–60

    Article  PubMed  Google Scholar 

  8. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivate dopamine agonists. Mov Disord 19:656–662

    Article  PubMed  Google Scholar 

  9. Kissner DG, Jarrett JC (1980) Side effects of bromocriptine. N Engl J Med 302:749–750

    Article  PubMed  CAS  Google Scholar 

  10. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11–18

    Article  PubMed  CAS  Google Scholar 

  11. Landolt AM, Keller PJ, Froesch ER, Mueller J (1982) Bromocriptine: does it jeopardise the result of later surgery for prolactinomas? Lancet 2:657–658

    Article  PubMed  CAS  Google Scholar 

  12. Losa M, Mortini P, Barzaghi R, Giola I, Giovanelli M (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87:3180–3186

    Article  PubMed  CAS  Google Scholar 

  13. Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55–65

    Article  PubMed  CAS  Google Scholar 

  14. Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW (2000) Gamma knife radiosurgery as primary treatment for prolactinomas. J Neurosurg 93(Suppl 3):10–13

    PubMed  Google Scholar 

  15. Pinero A, Marcos-Alberca P, Fortes J (2005) Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976–1977

    Article  PubMed  CAS  Google Scholar 

  16. Rains CP, Bryson HM, Cabergoline FA (1995) A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 49:255–279

    Article  PubMed  CAS  Google Scholar 

  17. Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22:239–246

    Article  PubMed  CAS  Google Scholar 

  18. Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenectomy in women with prolactinoma. N Engl J Med 309:280–282

    Article  PubMed  CAS  Google Scholar 

  19. Shristava RK, Arginteanu MS, King WA, Port KD (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299–306

    Article  Google Scholar 

  20. Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS Jr (2009) Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 12:158–164

    Article  PubMed  CAS  Google Scholar 

  21. Turner HE, Adams CB, Wass JA (1999) Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamin agonists? Eur J Endocrinol 140:43–47

    Article  PubMed  CAS  Google Scholar 

  22. Thomson JA, Davies DL, McLaren EH, Teasdale GM (1994) Ten year follow-up of microprolactinoma treated by transsphenoidal surgery. BMJ 309:1409

    Article  PubMed  CAS  Google Scholar 

  23. Tyrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1999) Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44:254–261

    Article  Google Scholar 

  24. Wang MY, Weiss MH (2001) Is there a role for surgery for microprolactinomas? Semin Neurosurg 12:289–294

    Google Scholar 

  25. Webster J (1996) A comparative review of the tolerability profiles of dopamin agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14:228–238

    Article  PubMed  CAS  Google Scholar 

  26. Webster J, Piscitelli G, Polli A, Cl F, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331:904–909

    Article  PubMed  CAS  Google Scholar 

  27. Zada G, Kelly DF, Cohan P, Wang C, Swerdloff R (2003) Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. J Neurosurg 98:350–358

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Laboratory of Neurooncology and Genetics, Institute of Neurosciences, Eiveniu g. 4, Kaunas, Lithuania

    Arimantas Tamasauskas, Andrius Radziunas, Daina Skiriute & Vytenis P. Deltuva

  2. Department of Neurosurgery, Hospital of Lithuanian University of Health Sciences Kauno klinikos, Eiveniu g. 2, Kaunas, Lithuania

    Arimantas Tamasauskas, Kestutis Sinkunas, Adomas Bunevicius, Andrius Radziunas & Vytenis P. Deltuva

Authors
  1. Arimantas Tamasauskas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kestutis Sinkunas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adomas Bunevicius
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrius Radziunas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daina Skiriute
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vytenis P. Deltuva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arimantas Tamasauskas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamasauskas, A., Sinkunas, K., Bunevicius, A. et al. Transsphenoidal surgery for microprolactinomas in women: results and prognosis. Acta Neurochir 154, 1889–1893 (2012). https://doi.org/10.1007/s00701-012-1450-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-012-1450-x

Keywords

Search

Navigation